Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Other Non-Current Assets (2024 - 2026)

Maze Therapeutics' Other Non-Current Assets history spans 3 years, with the latest figure at $1.1 million for Q1 2026.

  • On a quarterly basis, Other Non-Current Assets rose 1.01% to $1.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.1 million, a 1.01% increase, with the full-year FY2025 number at $3.0 million, down 61.25% from a year prior.
  • Other Non-Current Assets hit $1.1 million in Q1 2026 for Maze Therapeutics, down from $3.0 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for MAZE hit a ceiling of $7.9 million in Q4 2024 and a floor of $1.1 million in Q1 2025.
  • Historically, Other Non-Current Assets has averaged $2.5 million across 3 years, with a median of $1.1 million in 2025.
  • Biggest five-year swings in Other Non-Current Assets: tumbled 61.25% in 2025 and later increased 1.01% in 2026.
  • Tracing MAZE's Other Non-Current Assets over 3 years: stood at $7.9 million in 2024, then tumbled by 61.25% to $3.0 million in 2025, then crashed by 63.91% to $1.1 million in 2026.
  • Business Quant data shows Other Non-Current Assets for MAZE at $1.1 million in Q1 2026, $3.0 million in Q4 2025, and $1.1 million in Q3 2025.